GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (OTCPK:AVEFF) » Definitions » Days Sales Outstanding

AVEFF (Avecho Biotechnology) Days Sales Outstanding : 126.98 (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Avecho Biotechnology Days Sales Outstanding?

Avecho Biotechnology's average Accounts Receivable for the six months ended in Dec. 2024 was $0.36 Mil. Avecho Biotechnology's Revenue for the six months ended in Dec. 2024 was $0.52 Mil. Hence, Avecho Biotechnology's Days Sales Outstanding for the six months ended in Dec. 2024 was 126.98.

The historical rank and industry rank for Avecho Biotechnology's Days Sales Outstanding or its related term are showing as below:

AVEFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.37   Med: 130.08   Max: 447.8
Current: 157.68

During the past 13 years, Avecho Biotechnology's highest Days Sales Outstanding was 447.80. The lowest was 19.37. And the median was 130.08.

AVEFF's Days Sales Outstanding is ranked worse than
83.83% of 847 companies
in the Biotechnology industry
Industry Median: 72.4 vs AVEFF: 157.68

Avecho Biotechnology's Days Sales Outstanding declined from Dec. 2023 (2,818.61) to Dec. 2024 (126.98).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.


Avecho Biotechnology Days Sales Outstanding Historical Data

The historical data trend for Avecho Biotechnology's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Days Sales Outstanding Chart

Avecho Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.70 23.78 20.63 - 160.24

Avecho Biotechnology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.29 169.68 2,818.61 212.82 126.98

Competitive Comparison of Avecho Biotechnology's Days Sales Outstanding

For the Biotechnology subindustry, Avecho Biotechnology's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Days Sales Outstanding falls into.


;
;

Avecho Biotechnology Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Avecho Biotechnology's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 0.36) / 1 ) / 0.82*365
=0.36 / 0.82*365
=160.24

Avecho Biotechnology's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0.365 + 0.36) / 2 ) / 0.521*365 / 2
=0.3625 / 0.521*365 / 2
=126.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (OTCPK:AVEFF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Avecho Biotechnology Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines